Rubicon Research Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Rubicon Research Ltd filed with BSE on 19 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Rubicon Research reported Q1 FY27 revenue from operations of INR534 crores, EBITDA of INR131 crores, and PAT of around INR85 crores, representing year-on-year growth of 51%, 65%, and over 95% respectively. The quarter included the first consolidation impact of the Arinna Lifesciences acquisition, which contributed roughly INR12 crores to revenue with no material EBITDA impact. Management also announced the acquisition of a manufacturing facility in New Jersey, USA, progress on FDA compliance at the Pithampur site, and a leadership transition in which the CFO will move to a Chief Commercial Officer role.
Numbers mentioned
Revenue from operations: INR534 crores (Q1 FY27)
p. 3
“So if you look at our Q1 numbers, our revenue from operations came out to INR534 crores.”
Parag Sancheti, page 3 of the filed PDF · View the filing
EBITDA: INR131 crores (Q1 FY27)
p. 3
“EBITDA came out at INR131 crores.”
Parag Sancheti, page 3 of the filed PDF · View the filing
PAT: around INR85 crores (Q1 FY27)
p. 3
“PAT came out at around INR85 crores.”
Parag Sancheti, page 3 of the filed PDF · View the filing
Revenue growth year-on-year: 51% (Q1 FY27 vs Q1 FY26)
p. 3
“So if you just from a percentage growth, year-on-year revenue has grown by 51%, EBITDA has grown by 65%, and PAT has grown by more than 95%.”
Parag Sancheti, page 3 of the filed PDF · View the filing
Revenue from operation: INR5,343 million (Q1 FY27)
p. 3
“So our revenue from operation for the quarter was INR5,343 million, a growth of 52% versus the same quarter last year.”
Nitin Jajodia, page 3 of the filed PDF · View the filing
Gross profit: INR3,543 million (Q1 FY27)
p. 3
“Gross profit was INR3,543 million versus INR2,430 million in the Q1 previous year, again a strong growth of 46%.”
Nitin Jajodia, page 3 of the filed PDF · View the filing
Pre-R&D EBITDA margin: 35% (Q1 FY27)
p. 3
“Our pre-R&D EBITDA was at INR1,871 million, translating into 35% pre-R&D EBITDA margin versus 32.5% for the Q1 previous year.”
Nitin Jajodia, page 3 of the filed PDF · View the filing
R&D expense as percentage of revenue: 10.9% (Q1 FY27)
p. 3
“Our R&D expense for the quarter was INR580 million, translating into a 10.9% R&D as a percentage of revenue versus INR355 million in the quarter 1 previous year.”
Nitin Jajodia, page 3 of the filed PDF · View the filing
Operating EBITDA: INR1,291 million (Q1 FY27)
p. 3
“Our operating EBITDA for the quarter was INR1,291 million versus INR791 million in the quarter 1 previous year, again a strong growth of 63.2%.”
Nitin Jajodia, page 3 of the filed PDF · View the filing
Operating EBITDA margin: 24.2% (Q1 FY27)
p. 3
“And operating EBITDA margin was at 24.2% for the quarter 1 this year versus 22.4% previous year.”
Nitin Jajodia, page 3 of the filed PDF · View the filing
PAT: INR848 million (Q1 FY27)
p. 4
“So after that one-time other income, the PAT was at INR848 million versus INR433 million in the previous year, a strong growth of 96%.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
EPS: INR5.08 (Q1 FY27)
p. 4
“So overall a strong performance and EPS was at INR5.08.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
Capital employed: INR14,778 million (as on 30th June 2026)
p. 4
“As on that day, our capital employed was INR14,778 million, and it was after excluding cash and cash equivalent of INR2,408 million.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
Net working capital days: 114 days (as on 30th June 2026)
p. 4
“The net working capital for the quarter or as on 30th June '26 was 114 days versus 126 days as on 31st March '26.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
ROCE: 36% (Q1 FY27)
p. 4
“Our ROCE for the quarter was strong 36%.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
Operating cash flow before working capital change: INR1,390 million (Q1 FY27)
p. 4
“Our operating cash flow before working capital change for the quarter was INR1,390 million.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
Net cash flow from operating activity: INR285 million (Q1 FY27)
p. 4
“Our cash flow from net cash flow from operating activity was INR285 million.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
Top 5 products revenue contribution: 39% (Q1 FY27)
p. 4
“Top 5 products contributed 39% of the revenue in the Q1 and top 10 products contributed 55% of revenue in Q1.”
Parag Sancheti, page 4 of the filed PDF · View the filing
USD revenue: USD55 million (Q1 FY27)
p. 4
“Our USD revenues for Q1 was USD55 million, which was up 32% year-on-year from USD42 million.”
Parag Sancheti, page 4 of the filed PDF · View the filing
Commercialization rate: 88%
p. 5
“The commercialization rate remains strong at 88%.”
Parag Sancheti, page 5 of the filed PDF · View the filing
Specialty portfolio contribution to gross profit: 36% (Q1 FY27)
p. 5
“And also would like to highlight specialty portfolio contribution to gross profit for the quarter is 36%.”
Parag Sancheti, page 5 of the filed PDF · View the filing
Gross margin: 67.7% (Q1 FY27)
p. 5
“Our gross margin increased sequentially by around 140 bps to 67.7%.”
Parag Sancheti, page 5 of the filed PDF · View the filing
New Jersey facility purchase price: USD2.9 million
p. 6
“The total purchase price was USD2.9 million.”
Sagar Oak, page 6 of the filed PDF · View the filing
R&D productivity multiple: 5.5x (Q1 FY27)
p. 7
“And as you can see, our current R&D productivity based on this Q1 FY27 is about 5.5x.”
Sagar Oak, page 7 of the filed PDF · View the filing
R&D spend completed against nine-quarter guidance: INR251 crores of INR500 crores (five quarters)
p. 8
“We have completed spend of about INR251 crores out of INR500 crores in five quarters.”
Sagar Oak, page 8 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Net working capital days — 125 to 130 days
stated firmly by Nitin Jajodia
p. 4
“and we see working capital in the range of 125 to 130 days as we have guided earlier as well.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
Cash flow from operations — Q2 FY27
stated firmly by Nitin Jajodia
p. 4
“these refunds are getting normalized and we should see the impact of this in Q2 in terms of healthy cash flow for the quarter.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
Sequential USD revenue growth — Q2 FY27
stated firmly by Parag Sancheti
p. 5
“But Q2 FY27 is tracking strong for sequential USD revenue growth.”
Parag Sancheti, page 5 of the filed PDF · View the filing
EBITDA margin guidance — 23% · FY27
stated firmly by Parag Sancheti
p. 5
“But despite all these cost impact, we are slightly up guiding for around now earlier our guidance was 22% to 23% on EBITDA but now we are comfortable to revise this upwards for the whole of FY27 to 23%.”
Parag Sancheti, page 5 of the filed PDF · View the filing
Pithampur facility commercial ramp-up — Q1 calendar year 2027
stated firmly by Sagar Oak
p. 6
“So we are on track to ramp up commercial operations at this facility from first quarter of calendar year 2027 as we had previously guided.”
Sagar Oak, page 6 of the filed PDF · View the filing
New Jersey facility commercialization — calendar year 2027
stated firmly by Sagar Oak
p. 7
“We expect commercialization to start in calendar year 2027 once we have done once we are done with implementing our quality management systems at this site.”
Sagar Oak, page 7 of the filed PDF · View the filing
R&D spend — INR500 crores · nine quarters through Q1 FY28
stated firmly by Sagar Oak
p. 8
“So we believe we are on track to comfortably meet the INR500 crores spend guidance by Q1 of next year.”
Sagar Oak, page 8 of the filed PDF · View the filing
R&D spend as percentage of revenue — 10% to 11%
stated firmly by Sagar Oak
p. 8
“Since that has normalized to what is still an industry-leading 10% to 11%, which as we have previously stated, we will continue to hold.”
Sagar Oak, page 8 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said growth continues across older and newer products with a broad-based, range-bound concentration.
Answered by Management
Asked by Akshay: Color on top 10 product contribution, therapeutic areas, and maturity of products.
p. 10
“So as we mentioned earlier that our portfolio is pretty broad-based. If you look at the concentration of top 5, top 10 products over the years have continued to come down even if you look at last few quarters, it's range-bound.”
Management, page 10 of the filed PDF · View the filing
Management said the facility is strategic and expected to be margin accretive rather than dilutive.
Answered by Management
Asked by Sidharth Negandhi: Is the New Jersey facility expected to dilute or improve gross margins?
p. 12
“So from that perspective, this is a valued addition and we don't see margin I would say getting diluted because of this, okay. We definitely see that it will be in the overall scheme of thing should be margin accretive only.”
Management, page 12 of the filed PDF · View the filing
Management confirmed the INR12 crores revenue and immaterial EBITDA contribution, and described phased focus on growth before profitability.
Answered by Management
Asked by Harsh Kundnani: Did Arinna contribute INR12 crores to revenue with flattish EBITDA impact, and how will Arinna margins evolve?
p. 15
“Yes, so you're right, the revenue contribution was close to INR12 crores and the EBITDA contribution on that INR12 crores revenue was not material.”
Management, page 15 of the filed PDF · View the filing
Management described a long, court-supervised bankruptcy process and an existing adjacent site giving them an advantage.
Answered by Management
Asked by Tushar Manudhane: How did Rubicon acquire the New Jersey facility at a low purchase price?
p. 16
“It was a court-supervised bankruptcy and I think we were able to stay the distance.”
Management, page 16 of the filed PDF · View the filing
Management confirmed the shift toward higher-margin business alongside rising specialty share of gross profit.
Answered by Management
Asked by Prateek Shrivastava: Has Rubicon secured new higher-margin US business after walking away from lower-margin business?
p. 18
“So in a way, Yes, that's correct. And again, also look at also look at that if we are letting go of a relatively lower margin business, okay, in that choice making, we will do that only if we are securing a higher margin business.”
Management, page 18 of the filed PDF · View the filing
Management said that figure is now disclosed only once a year.
Answered by Management
Asked by Prateek Shrivastava: Why was the number of products under FDA review not disclosed this quarter?
p. 19
“So we shared that in the last quarter and then we'll be sharing that number once in a year.”
Management, page 19 of the filed PDF · View the filing
Risks flagged
Increased reliance on contract manufacturing pressuring gross margins due to stronger than anticipated revenue traction and manufacturing constraints.
p. 5
“In Q3 FY26 update, we had flagged off that stronger than anticipated revenue traction coupled with our own constraint in manufacturing was leading to a larger reliance on contract manufacturing which was pressurizing our GM and company was in looking to do certain tactical measures to ensure that we are able to meet the demand but at the same time, we are also focused on the gross margin piece of it.”
Parag Sancheti, page 5 of the filed PDF · View the filing
Sequential increase in input and freight costs due to geopolitical conditions.
p. 5
“This is despite we have had sequential increase in key input cost, freight cost due to the geopolitical conditions.”
Parag Sancheti, page 5 of the filed PDF · View the filing
Specific cost items expected to impact EBITDA margins for the remainder of FY27, including ESOP costs, Arinna kickstart costs, and pre-revenue costs for new facilities.
p. 5
“For the remaining three quarters, I also want to point out in FY27, we would some specific costs which could impact EBITDA margins such as ESOP cost which is arising from the new ESOP scheme, Arinna costs which are related to kickstarting the growth for Arinna, and the pre-revenue cost for the new facility which we've acquired in New Jersey and Pithampura.”
Parag Sancheti, page 5 of the filed PDF · View the filing
Delay in GST refunds impacting operating cash flow for the quarter.
p. 4
“In this quarter, the cash flow was impacted because of some delay in GST refunds and these refunds are getting normalized and we should see the impact of this in Q2 in terms of healthy cash flow for the quarter.”
Nitin Jajodia, page 4 of the filed PDF · View the filing
FDA unannounced inspection at Pithampur resulted in a 483 with two observations.
p. 6
“So in early July, we had informed that the FDA conducted an unannounced inspection. A 483 was issued with two observations which we had said we were confident of concluding the evaluation in a timely way.”
Sagar Oak, page 6 of the filed PDF · View the filing
Prior FDA inspection at the New Jersey facility resulted in a 483 with six observations.
p. 6
“You may recall that at that point in time, the FDA had issued a 483 with six observations which we believed were largely procedural.”
Sagar Oak, page 6 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.